ERBB2 and neoplasm: In the postneoadjuvant setting, patients with residual triple-negative disease showed improved oncologic outcomes when receiving capecitabine as did patients with residual ERBB2-positive disease when receiving trastuzumab emtansine–DM1.11,12 In both trials, patients with tumor-positive lymph nodes were also eligible.